Manganese doped upconversion luminescence nanoparticles
View Patent ↗The present relates in general to upconversion luminescence (“UCL”) materials and methods of making and using same and more particularly, but not meant to be limiting, to Mn 2+ doped semiconductor nanoparticles for use as UCL materials. The present invention also relates in general to upconversion luminescence including two-photon absorption upconversion, and potential applications using UCL materials, including light emitting diodes, upconversion lasers, infrared detectors, chemical sensors, temperature sensors and biological labels, all of which incorporate a UCL material.
1. A method of using a bioconjugated upconversion luminescent nanoparticle system for biological labeling, comprising the steps of:
delivering a bioconjugated upconversion luminescent nanoparticle system to a target,
binding the bioconjugated upconversion luminescent nanoparticle system to the target, and
measuring upconversion luminescence from the bioconjugated upconversion luminescent nanoparticle system bound to the target, wherein an emission wavelength of the bioconjugated upconversion luminescent nanoparticle is shorter than an excitation wavelength of the bioconjugated upconversion luminescent nanoparticle, wherein the upconversion luminescent nanoparticle of the bioconjugated upconversion luminescent nanoparticle system has the general formula (X):(Mn, R), wherein
(X) is a host having a size less than 100 nm and is represented by the formula (M 1-z N z ) 1-x A 1-y B y where M=Zn, Cd, Pb, Ca, Ba, Sr, and Mg; N=Zn, Cd, Pb, Ca, Ba, Sr, and Mg; A=S, Se, Te, and O; B=S, Se, Te, and O, wherein 0≦x<1, 0<y≦1, 0<z≦1, and
(R) is a rare earth ion.
2. The method of claim 1 , wherein the emission wavelength is 750 nm and the excitation wavelength is 980 nm.
3. The method of claim 1 , wherein the host is selected from the group consisting of Zn 1-x S y , Zn 1-x Se y , Zn 1-x Te y , Cd 1-x S y , Cd 1-x Se y , Cd 1-x Te y , Pb 1-x S y , Pb 1-x Se y , Pb 1-x Te y , Mg 1-x S y , Ca 1-x S y , Ba 1-x S y and Sr 1-x S y , wherein 0≦x<1, and 0<y≦1.
4. The method of claim 1 , wherein the nanoparticle host is Zn 0.4 Cd 0.4 S.
5. The method of claim 1 , wherein the nanoparticle host is Zn 0.9 S 0.8 Se 0.2 .
6. The method of claim 1 , wherein the rare earth ion is selected from the group consisting of Eu 3+ , Tb 3+ , Ce 3+ or Er 3+ .
7. The method of claim 1 , wherein the upconversion luminescent nanoparticle is selected from the group consisting of ZnS:Mn,Er; ZnSe:Mn,Er; MgS:Mn,Er; CaS:Mn,Er; ZnS:Mn,Yb; ZnSe:Mn,Yb; MgS:Mn,Yb; CaS:Mn,Yb and ZnS:Mn, Eu.
8. The method of claim 7 , wherein the upconversion luminescent nanoparticle of the bioconjugated upconversion luminescent nanoparticle system is ZnS:Mn,Yb.
9. The method of claim 1 , wherein the bioconjugate component of the bioconjugated upconversion luminescent nanoparticle system is selected from the group consisting of antibodies, antigens, proteins, lipids, sugars, liposomes, bacteria, DNA, RNA and combinations thereof.
10. The method of claim 9 , wherein the bioconjugate component of the bioconjugated upconversion luminescent nanoparticle system is bovine serum albumin.
11. The method of claim 1 , wherein the bioconjugated upconversion luminescent nanoparticle system comprises upconversion luminescent nanoparticles and biomolecules that are linked by bioconjugation.
12. The method of claim 1 , wherein the bioconjugated upconversion luminescent nanoparticle system comprises upconversion luminescent nanoparticles and biomolecules that are linked by chemical bonds.
13. The method of claim 1 , wherein the bioconjugated upconversion luminescent nanoparticle system comprises upconversion luminescent nanoparticles and biomolecules that are linked by a ligand bound to a receptor.
14. The method of claim 1 , wherein the method is performed in vivo.
15. The method of claim 1 , wherein the method is performed in vitro.
16. The method of claim 1 , wherein the target is selected from the group consisting of a tumor or a bacterial agent.
17. The method of claim 16 , wherein the target is Escherichia coli.
18. The method of claim 16 , wherein the target is cholera.
19. The method of claim 1 , wherein the target is chosen from the group consisting of cell components, DNA, DNA sequences, proteins, and antibodies.